GlassScriptPhysician profile
Lisa S Bunin
NPI 1154397875
$16,670.61
in general payments reported to CMS, 2019-2025
30 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,674 · 2020: $512 · 2021: $5,077 · 2022: $2,447 · 2023: $2,856 · 2024: $917 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351 · Travel and Lodging: $1,511 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.59 |
| Travel and Lodging | $1,511.32 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $5,789.21 | 2019-2025 | |
| Allergan, INC. | $2,414.69 | 2019-2022 | |
| Abbvie INC. | $2,163.94 | 2022-2025 | Durysta, Lumigan, Vuity |
| Eyevance Pharmaceuticals LLC | $1,182.94 | 2019-2022 | |
| Merz North America, INC. | $985.82 | 2019-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $546.64 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $502.91 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $473.96 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Mallinckrodt Hospital Products INC. | $454.33 | 2022-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $275.10 | 2019-2023 | |
| Oyster Point Pharma, INC. | $269.09 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.77 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $167.50 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $153.32 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $140.61 | 2024-2025 | Xdemvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $126.86 | 2023-2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $123.50 | 2022 | |
| Apellis Pharmaceuticals, INC. | $114.89 | 2023 | Syfovre |
| Spark Therapeutics, INC. | $106.68 | 2019 | |
| Horizon Therapeutics Plc | $105.02 | 2022-2023 | Tepezza |
| Dompe US, INC. | $92.22 | 2025 | Oxervate |
| Galderma Laboratories, L.P. | $45.35 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $41.65 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $39.62 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Omeros Corporation | $35.28 | 2019-2020 | |
| Shire North American Group INC | $19.46 | 2019 | |
| Ocular Therapeutix, INC. | $18.93 | 2023 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $17.62 | 2022 | |
| Alcon Research LLC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Bunin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.